Pasar al contenido principal

INTERFERENCIA ENTRE LA ACETILACION Y LA FOSFORILACION EN LA ENFERMEDAD DE ALZHEIMER: PAPEL DE LAS SIRTUINAS 3 Y 7 EN NEURODEGENERACION OLFATORIA

PID2023-152593OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2023
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION MIGUEL SERVET

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Microglial SIRT2 deficiency aggravates cognitive decline and amyloid pathology in Alzheimer's disease

  • Sola-Sevilla, Noemi
  • Garmendia-Berges, Maider
  • Aleixo, Mikel
  • Mera-Delgado, MCarmen
  • Solas, Maite
  • Tordera, Rosa M
  • García-Carracedo, Lucía
  • Expósito, Sara
  • Anaya-Cubero, Elena
  • Fernández-Irigoyen, Joaquín
  • Guruceaga, Elisabeth
  • Santamaria, Enrique
  • Martin, Eduardo D
  • Puerta, Elena
Sirtuin 2 (SIRT2), a NAD+-dependent deacetylase, has been implicated in aging and neurodegenerative diseases such as Alzheimer's disease (AD). While global SIRT2 inhibition has shown promise in reducing amyloid-beta pathology and cognitive deficits in different mouse models of AD, peripheral SIRT2 inhibition has been associated with adverse effects, such as increased inflammation. This suggests that targeted inhibition of specific cellular populations within the brain may represent a more precise and effective approach for the treatment of AD. To explore this hypothesis, we generated a conditional microglial SIRT2 knockout mouse model in the context of AD. Our results reveal that microglial SIRT2 reduction does not confer protective effects in the APP/PS1 model; rather, it aggravates cognitive decline, accelerates amyloid plaque deposition, and increases levels of pro-inflammatory cytokines at early stages of AD pathology. Transcriptomic analysis further indicates that SIRT2-deficient microglia exhibit altered expression of genes associated with aging and synaptic dysfunction. This phenotype was accompanied by increased phagocytosis of PSD95 and impaired long-term potentiation. These findings suggest that while SIRT2 inhibition in some contexts may be beneficial, targeted inhibition within microglia could accelerate AD progression, underscoring the need for cell-specific approaches when considering SIRT2 as a therapeutic target., This work was supported by grant PID2020-119729GB-I00 funded by MICIU/AEI/ 10.13039/501100011033 to EP and partially by grant PID2023-152593OB-I00 funded by 501100011033 / FEDER, UE to ES and JFI., Peer reviewed
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación Artículo científico (JournalArticle)

Early, sex-dependent and progressive proteomic imbalance in the amygdala during Alzheimer's disease continuum

  • Romero-Murillo, Silvia
  • Lachén Montes, Mercedes
  • Cartas Cejudo, Paz
  • Anaya-Cubero, Elena
  • Miguel, Marina de
  • Extramiana, Leire
  • Ferrer, Isidro
  • Fernández Irigoyen, Joaquín
  • Santamaría Martínez, Enrique
Background: The amygdala is involved in the emotional expression, memory processing and managing stimulatory input. Although amygdala atrophy is early evidenced in Alzheimer's Disease (AD), the molecular mechanisms disrupted in initial neuropathological stages are still unknown. In the present study, we investigated the proteomic impairment of the amygdaloid region from AD-Braak stage I-II and III-IV subjects to better understand the neuropathological processes occurred early in this area and to identify potential targets that may face AD from the beginning of the disease. Methods: Label-free quantitative proteomics was applied using an Orbitrap Exploris 480 mass-spectrometer in 24 postmortem amygdala specimens derived from non-demented (n = 3F/5M), AD-Braak stage I-II (n = 4F/4M) and AD-Braak stage III-IV (n = 4F/4M). Data analysis was performed using MaxQuant and Perseus software (two-way Student T-test; p < 0.05). Metascape and Ingenuity Pathway Analysis softwares were considered for biological interpretation. Connectivity map platform was used for drug repurposing analyses. Transcriptomic/proteomic data of other brain regions were obtained from AlzData, Neuropro, and Agora repositories. Results: Amygdaloid proteome of AD-Braak stage I-II and III-IV subjects compared to controls revealed a progressive proteomic impairment with a minimal overlap across Braak stages. Some of the amygdaloid DEPs were known interactors of human A¿ plaques, APP, or Tau proteins or were previously identified at transcriptional or translational level in other brain regions affected by AD. Interestingly, amygdaloid proteome was more severely affected in women than in men with a particular protein expression profile associated to each AD stage. Comparing our sex-dependent differential proteome datasets with transcriptomic data of different brain regions, we identified potential sex-specific proteins related to cognitive decline and neurodegeneration. Finally, data-driven drug repositioning using amygdaloid omics profiles unveiled that most of the small molecule candidates were neuropathological stage and/or sex-specific. Conclusions: Early and sex-specific amygdaloid proteome dysregulation in AD highlights the consideration of a deliberate stratification by sex in future research and clinical trials to develop effective therapeutic strategies in AD for both sexes. Plain english summary: The amygdala is a brain region involved in the expression of emotions, memory processing and managing incoming stimulus. Atrophy of this area is evidenced at the first stages of Alzheimer¿s Disease (AD), pointing out a potential involvement of amygdala in the pathology of this disease. However, the molecular changes occurred early in this area are not fully understood. To this end, we interrogated the proteome of amygdala postmortem samples came from subjects of early AD stages. By applying data and functional analyses, we observed a stage-dependent and progressive proteomic impairment in this area. We detected proteins differentially expressed that were already known to interact with well-stablished neuropathological proteins or were altered in other brain areas. Importantly, data stratification by sex revealed that protein expression changes of amygdala were more abundant in women than men across AD progression. After comparing our results with published data in different brain regions affected by AD, we identified sex-specific proteins that could be used as biomarkers of cognitive decline and neurodegeneration. Finally, a drug repositioning-based approach proposed candidates with the potential to reverse amygdaloid malignant AD signature more effectively in one sex than in other or just in one sex. These observations highlight the consideration to include sex differences in future research to develop more precise and effective treatments in AD., The Clinical Neuroproteomics Unit of Navarrabiomed is a member of the Spanish Olfactory Network (ROE) (supported by grant RED2022-134081-T funded by Spanish Ministry of Science and Innovation). The Clinical Neuroproteomics Unit is supported by grants PID2023-152593OB-I00 funded by MCIU/AEI/ 10.13039/501100011033 / FEDER, UE to ES and JFI and 0011-1411-2023-000028 (from Government of Navarra-Department of Economic and Business Development-S4) to ES. Paz Cartas-Cejudo is supported by a postdoctoral fellowship from Public University of Navarra (UPNA).
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación Artículo científico (JournalArticle)

Microglial SIRT2 deficiency aggravates cognitive decline and amyloid pathology in Alzheimer's disease

  • Sola-Sevilla, Noemi
  • Garmendia-Berges, Maider
  • Aleixo, Mikel
  • Mera-Delgado, Mª Carmen
  • Solas, Maite
  • Tordera, Rosa M.
  • García-Carracedo, Lucía
  • Expósito, Sara
  • Anaya-Cubero, Elena
  • Fernández Irigoyen, Joaquín
  • Guruceaga, Elizabeth
  • Santamaría Martínez, Enrique
  • Martín, Eduardo D.
  • Puerta, Elena
Sirtuin 2 (SIRT2), a NAD+-dependent deacetylase, has been implicated in aging and neurodegenerative diseases such as Alzheimer's disease (AD). While global SIRT2 inhibition has shown promise in reducing amyloid-beta pathology and cognitive deficits in different mouse models of AD, peripheral SIRT2 inhibition has been associated with adverse effects, such as increased inflammation. This suggests that targeted inhibition of specific cellular populations within the brain may represent a more precise and effective approach for the treatment of AD. To explore this hypothesis, we generated a conditional microglial SIRT2 knockout mouse model in the context of AD. Our results reveal that microglial SIRT2 reduction does not confer protective effects in the APP/PS1 model; rather, it aggravates cognitive decline, accelerates amyloid plaque deposition, and increases levels of pro-inflammatory cytokines at early stages of AD pathology. Transcriptomic analysis further indicates that SIRT2-deficient microglia exhibit altered expression of genes associated with aging and synaptic dysfunction. This phenotype was accompanied by increased phagocytosis of PSD95 and impaired long-term potentiation. These findings suggest that while SIRT2 inhibition in some contexts may be beneficial, targeted inhibition within microglia could accelerate AD progression, underscoring the need for cell-specific approaches when considering SIRT2 as a therapeutic target., This work was supported by grant PID2020-119729GB-I00 funded by MICIU/AEI/ 10.13039/501100011033 to EP and partially by grant PID2023-152593OB-I00 funded by MCIU/AEI/ 10.13039/ 501100011033 / FEDER, UE to ES and JFI.
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación Artículo científico (JournalArticle)

Impact of medication use on olfactory performance in older adults

  • Izco-Cubero, Maite
  • Zambom Ferraresi, Fabíola
  • Zambom Ferraresi, Fabrício
  • Fernández González de la Riva, María Luisa
  • Santamaría Martínez, Enrique
  • Fernández Irigoyen, Joaquín
  • Lachén Montes, Mercedes
  • Lasarte, Juan José
  • Uzcanga Lacabe, María Iciar
  • Fernández, Secundino
  • Sanjurjo San Martín, Gloria
  • Maravi Aznar, Enrique
  • Martínez Velilla, Nicolás
Introduction: Olfactory dysfunction impacts quality of life, safety, and nutrition. Despite its relevance among older adults, the role of medications in influencing olfactory performance remains understudied. This research investigates whether olfactory alterations in older adults are associated with the type or number of medications prescribed. Methods: An observational cross-sectional study was conducted with 107 participants (mean age of 86.1 ± 5.1 years). Olfactory performance was evaluated using the Sniffin’ Sticks Test (SST). Functional capacity, cognitive function and the number and type of medications were also assessed. Results: The analysis demonstrated a correlation between better olfactory performance and higher cognitive function. An inverse correlation was found between the age of participants and olfactory identification. While polypharmacy (intake of five or more medications) did not show a significant association with olfactory dysfunction, the intake of laxatives was associated with poorer olfactory threshold performance (−1.21, 95% CI −2.07 to −0.34; p = 0.008). In contrast, proton pump inhibitors (PPIs) (1.14, 95% CI 0.07 to 2.21; p = 0.04) and vitamin D (1.09, 95% CI 0.03 to 2.15; p = 0.04) intake were linked to improved olfactory identification. Discussion: These findings suggest that certainmedications influence olfactory performance; however, further research is needed to clarify the effects of different drug classes on olfaction., The Clinical Neuroproteomics Unit is member of the Spanish Olfactory Network -ROE (grant RED2022-134081-T from the Spanish Ministry of Science & Innovation) and is supported by grants PID2023-152593OB-I00 funded by MCIU/AEI/ 10.13039/501100011033 / FEDER, UE to and 0011-1411-2023-000028 from Government of Navarra (Department of Economic and Business Development-S4).
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación Artículo científico (JournalArticle)

The potential of proteomics for in-depth molecular investigations of progressive supranuclear palsy

  • Romero-Murillo, Silvia
  • Lee, Seojin
  • Fernández Irigoyen, Joaquín
  • Martínez-Valbuena, Iván
  • Santamaría Martínez, Enrique
Introduction: progressive supranuclear palsy (PSP) is a rare neurodegenerative disorder. The lack of comprehension about the pathogenesis of the disease, its heterogeneity, and the complex clinical evaluation in early stages, limit the development of effective treatments for PSP patients and highlight the need of further research on the field. Areas covered: in this work, we review the current knowledge of the physio- and neuropathology of PSP, its clinical features, diagnosis markers, and treatment options. We also compare the proteomic-based studies done to date in brain tissues as well as in cerebrospinal fluid and other non-cerebral samples, briefly describing the proteomic approach used and the biological findings obtained in each study. Expert opinion: PSP is a complex neurodegenerative disorder marked by tau aggregation, glial dysfunction, and neuroinflammation. Although advances in neuroimaging and biofluid biomarkers have improved PSP diagnostic accuracy, no disease-modifying therapies are currently available. Promising avenues such as tau PET tracers, seed amplification assays, and advanced proteomic-based approaches are enhancing our ability to detect disease-specific tau pathology and hold the potential to provide novel biomarkers for earlier and more precise clinical diagnosis and treatment development that could transform the landscape of PSP., The Clinical Neuroproteomics Unit is supported by grants PID2023-152593OB-I00 funded by MCIU/AEI/10.13039/501100011033/FEDER, UE to ES and JFI and 0011-1411-2023-000028 (from Government of Navarra- Department of Economic and Business Development-S4).